Opko Health (OPK) Shares Gap Down to $1.96

Shares of Opko Health Inc. (NASDAQ:OPK) gapped down prior to trading on Tuesday . The stock had previously closed at $1.87, but opened at $1.96. Opko Health shares last traded at $2.00, with a volume of 8218717 shares.

Several analysts recently commented on the company. ValuEngine lowered Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Tuesday, April 30th. Finally, Barrington Research reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Opko Health in a report on Thursday, February 28th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $9.25.

The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -8.04 and a beta of 1.81. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.10 and a quick ratio of 0.96.

Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.08). The company had revenue of $222.50 million for the quarter, compared to analysts’ expectations of $241.27 million. Opko Health had a negative net margin of 19.92% and a negative return on equity of 9.86%. Opko Health’s revenue for the quarter was down 12.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.08) earnings per share. On average, analysts expect that Opko Health Inc. will post -0.2 EPS for the current fiscal year.

In related news, Director Richard C. Pfenniger, Jr. bought 50,000 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average cost of $2.05 per share, for a total transaction of $102,500.00. Following the completion of the transaction, the director now owns 171,310 shares of the company’s stock, valued at $351,185.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Phillip Md Et Al Frost bought 20,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were bought at an average price of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $7,917,893.58. The disclosure for this purchase can be found here. Insiders have purchased 2,108,250 shares of company stock worth $4,725,980 over the last quarter. 42.74% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Diversified Trust Co purchased a new position in shares of Opko Health in the fourth quarter valued at about $30,000. Piedmont Investment Advisors Inc. purchased a new position in shares of Opko Health in the first quarter valued at about $27,000. FDx Advisors Inc. purchased a new position in shares of Opko Health in the fourth quarter valued at about $33,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Opko Health in the first quarter valued at about $39,000. Finally, Meeder Asset Management Inc. lifted its position in shares of Opko Health by 58.7% in the first quarter. Meeder Asset Management Inc. now owns 13,102 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 4,846 shares in the last quarter. Institutional investors own 22.66% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thelincolnianonline.com/2019/05/14/opko-health-opk-shares-gap-down-to-1-96.html.

Opko Health Company Profile (NASDAQ:OPK)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Featured Article: Differences Between Momentum Investing and Long Term Investing

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.